GeneHealth's Mission and Services
We provide physicians with a tool for leveraging genetic knowledge to offer individualized, effective care through:
- An in-depth report on a GeneHealth member's unique disease susceptibility based on their genetic makeup.
- Likelihood measurements for each potential disease.
- A drug metabolism report to analyze a GeneHealth member's unique drug responses.
How it all Works
Led by pioneering scientists, GeneHealth.AI:
- Has developed a groundbreaking AI-driven pipeline aimed at pinpointing patient-specific driver proteins that contribute to disease development.
- Can suggest repurposable applications of FDA-approved for research purposes, offering new avenues for effective treatment.
- Is able to examine the intricate interactions among multiple disease-driving proteins, unlike traditional precision medicine methods that focus on individual proteins.
- Accurately identifies which variants of unknown significance (VUS) are likely associated with diseases, providing deeper insights for healthcare professionals.
- Provides continuous input from the community allowing for real-time updates and adaptations in treatment plans, ensuring they are current and effective.
- Crowdsources data to help identify the most effective treatments for specific genetic makeups, leading to improved treatment outcomes.
Our Team
Chris Klaus
Co-founder & Co-CEO
Chris Klaus is a successful entrepreneur and a visionary leader in the field of genetics and artificial intelligence. He has been a founder and CEO of Kaneva, and is a partner in CyberLaunch, a startup accelerator focused on growing security and machine learning startups. Prior to founding Kaneva, Klaus established Internet Security Systems Inc. (ISS) in 1994. He plays a pivotal role in GeneHealth.AI's mission to revolutionize healthcare through the use of genetic knowledge and AI. Chris is deeply committed to leveraging genetic insights to provide individualized, effective care and make personalized health a reality.
Jeffrey Skolnick, PhD
Co-founder & Co-CEO
Dr. Jeffrey Skolnick, Regents' Professor, Mary and Maisie Gibson Chair, and GRA Eminent Scholar in Computational Systems Biology, is a driving force behind GeneHealth.AI's innovation. His pioneering research and expertise in drug development have been instrumental in shaping AI tools like Medicascy and LeMeDISCO. These tools excel in identifying precise disease-associated variants of unknown significance. Driven by a passion for improving health outcomes, he remains committed to leveraging genetic insights, providing personalized care, and creating new possibilities for people with intractable diseases.
Careers
Join our team and revolutionize healthcare through genetics and artificial intelligence. We're looking for talented individuals with experience in bioinformatics, cheminformatics, or computational biology, and software engineers with experience in full stack development and AWS. Send your resume to careers@genehealth.ai.